Redeye provides a comment on today's news in Scandinavian ChemoTech regarding the separation of Huma...
The Board of PMD Device Solutions has filed for bankruptcy following extensive reviews of the compa...
Tangiamo Touch Technology (”Tangiamo” eller ”bolaget”) meddelade den 19 december 2024 att bolaget ha...
Nettoomsättningen uppgick till 53,1 MSEK (50,0) i det andra kvartalet (aug-okt) i Purefuns brutna rä...
Redeye provides a brief comment on Mendus announcing that Institut Bergonié terminated the collabora...
Redeye updates its estimates and fair value range following Ngenic’s share issue announcement and Q3...
Redeye comments on the recent funding by Smart Eye’s main competitor, Seeing Machines, which has ent...
Neovici AB (”Neovici” eller Bolaget” )meddelade den 20 december att bolaget har ingått avtal avseend...
Redeye comments on Freemelt’s plan to resolve a SEK100m rights issue, with 90% secured through subsc...
On December 20, 2024, the Swedish Inspectorate of Strategic Products (ISP) concluded its review of X...
Accenture Q1'25 grew 8% (+3% vs cons), driven by a broad base Raises FY guidance from 3-6% growth to...
Bolaget börjar gradvis få en stabilare tillväxt och jobbar mer intensivt med distributörerna i syfte...
On December 18th, STENOCARE announced that the company has resolved a rights issue of up to DKK 20.
Redeye is encouraged by Sivers Semiconductors’ announcement of a strengthened partnership framework ...
Enersense's wind power development portfolio has been divested, and losses from non-core operations ...
Redeye gives a brief comment on FMG’s downward revision of its full-year guidance.
Redeye comments on Egetis investor day yesterday, that focused on the commercialization of Emcitate ...
AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 19 december år 2024 att Bolaget har lämnat in en I...
Förra veckan aviserade kontraktstillverkaren Hanza förvärvet av finska Leden Group, en ledande kontr...
Redeye endorses the news that BioArctic has signed a licensing agreement with BMS regarding BioArcti...
